W. Schmidmeier

Boston Children's Hospital

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

W Hinterberger

Donauspital

Helmut Gadner

St Anna Children's Hospital

Peter Bettelheim

Krankenhaus der Elisabethinen

Klaus Lechner

Medical University of Vienna

A Hajek-Rosenmayr

University of Vienna

G Stingl

University of Vienna

P Krepler

Medical University of Vienna

E. Pichler

Psychiatry Baselland

Beatrix Volc‐Platzer

Medical University of Vienna

W Kallinger

Klinik Hietzing

Cooperative Institutions

University of Vienna

Medical University of Vienna

St Anna Children's Hospital

Vienna General Hospital

Universitätszahnklinik Wien

Ludwig Boltzmann Institute for Digital Health and Prevention

University of Graz

Klinik Hietzing

University of Münster

Ludwig Boltzmann Institute for Experimental and Clinical Traumatology

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Attempt for a Complete Protocol of TBI

Springer eBooks (1985)

W Kallinger G Alth George Müller W. Hinterberger H Kolbabek

10.1007/978-3-662-40457-7_22

Cite

Citations (1)

Treatment of Severe Aplastic Anemia with Combined Immunosuppression (Antithymocyte Globulin and High-Dose Methylprednisolone)

Acta Haematologica (1986)

M Hinterberger-Fischer W Hinterberger P. Höckern W. Schmidmeier Helmut Gadner

Fifteen patients with transfusion-dependent severe aplastic anemia (SAA) were treated with combined immunosuppression consisting of horse-antithymocyte globulin (ATG; Atgam, Upjohn) and high-dose 6-methylprednisolone (MP). Oxymetholone was scheduled for 2 years but was discontinued in 7 patients after 10-385 days due to liver toxicity. Serious side effects usually seen in ATG monotherapy were rare during combined immunosuppression. Currently 12 of 15 patients are alive 110-1,275 days (median 475.5) after start of treatment. One patient has received too short treatment to be evaluated. All the others are transfusion-independent. Three patients died; two from septicemia before hemopoietic recovery could be expected and one after relapse. Our results confirm that the addition of high-dose MP abrogates the side effects of ATG monotherapy, and the addition of MP does not counteract, but rather enhances the beneficial effect of ATG in SAA. We recommend combined immunosuppressive treatment with ATG and high-dose MP as a highly feasible, safe and effectful therapy for patients with transfusion-dependent SAA.

Immunosuppression

Aplastic anemia

10.1159/000206055

Cite

Citations (16)

Con A-induced suppressor cells in children with acute lymphoblastic leukaemia.

PubMed (1980)

M Eibl P Krepler W. Schmidmeier C C Zielinski H. Winterleitner

The function of Con A stimulation was investigated in patients with ALL in remission and in patients with ALL in the acute phase of the disease as compared to healthy controls. Suppression of the Con A response brought about by autologous Con A-activated cells was significantly lower in ALL patients in remission (mean value 29.33%) and in the acute phase (mean value 10%) than in the controls (mean value 64.86%). Suppression of the Con A stimulation of control lymphocytes by Con A-activated homologous cells of ALL patients had a mean value of 51.65%. This was significantly higher than the suppression obtained by the same ALL cells in the autologous system and of the same order of magnitude as the suppression obtained by control Con A-activated cells on control Con A stimulation (57.67%). Suppression of the Con a response of ALL lymphocytes produced by control Con A-activated cells was 23.17% and comparable to healthy controls. These results demonstrate that the function of Con A-induced suppression is significantly lower in ALL patients. They further indicate that at least two cell types are involved in this kind of suppression in humans.

Source

Cite

Citations (4)

Cytogenetic studies in bone marrow transplant recipients

Blut Zeitschrift für die gesamte Blutforschung (1986)

Oskar A. Haas W Hinterberger W. Schmidmeier Christine Pollak Maria Hinterberger

Philadelphia chromosome

Blast Crisis

10.1007/bf00320580

Cite

Citations (16)

Conventional vs. Liposomal Amphotericin B in Immunosuppressed Children

Pediatric Hematology and Oncology (1992)

A. Zoubek Wolfgang Emminger W. Schmidmeier Craig A. Peters Elisabeth Pracher

Invasive fungal infections, mostly caused by Candida and Aspergillus species, are a major cause of early morbidity and mortality in immunocompromised children. 1,2 The treatment of choice for systemic fungal infections is still the early intravenous administration of amphotericin B. 3 However, conventional AMB therapy is often limited by severe side effects such as fever, chills, bronchospasm, and nephrotoxicity. 2 In recent reports liposomal AMB (AmBisome) was shown to be effective in the treatment of severe systemic fungal infections. 4,5 So far, clinical experience with AmBisome in children is still anecdotal and no comparative study is yet available. In the following we report on 11 immunosuppressed children who were treated with conventional or liposomal AMB for longer than 3 weeks.

Chills

Nephrotoxicity

Amphotericin B deoxycholate

10.3109/08880019209018337

Cite

Citations (35)

A suggestion to change the TBI protocol of the IBMTR.

PubMed (1986)

W Kallinger G Alth Ronald Richter H Kolbabek W. Hinterberger

Total body irradiation

Source

Cite